Manufacturing Capacity to Meet the Demands of Industry Partners
Tosoh Bioscience’s process media portfolio enables flexible, scalable purification strategies tailored to diverse oligonucleotide modalities.
As of May 2026, Tosoh Bioscience has opened GT-4 manufacturing plant, increasing our resin manufacturing capacity by 70%! The nucleic acid-based therapy market is rapidly growing, and we are here to support our industry partners efficiently scale up their purification workflows with a process media portfolio tailored to increasingly diverse oligonucleotide modalities.
What Tosoh Bioscience Brings to the Table:
✓ Robust manufacturing of resin dedicated to oligonucleotide purification
✓ Durable, methacrylic polymer resins with high chemical and mechanical stability
✓ Complementary selectivity across AEX and HIC modes
MAKE IT RELIABLE. MAKE IT TOSOH.